Jaime Espin
Overview
Explore the profile of Jaime Espin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rejon-Parrilla J, Epstein D, Perez-Troncoso D, Espin J
Health Econ Policy Law
. 2025 Jan;
:1-18.
PMID: 39881538
Although the criteria that support reimbursement decisions for medicines are often set by legislation, as is the case in Spain, in many cases neither the definition nor the measurement methods...
2.
Roca Oporto F, Espin J, Andrades Gomez C, Montilla Cosano G, Sanchez-Pozo M, Rocha J
Kidney Int Rep
. 2025 Jan;
10(1):265-266.
PMID: 39810782
No abstract available.
3.
Vogler S, Zimmermann N, Knoll V, Salcher-Konrad M, Windisch F, Espin J, et al.
J Pharm Policy Pract
. 2025 Jan;
17(Suppl 1):2442002.
PMID: 39763616
On 25-26 April 2024, the 5th PPRI (Pharmaceutical Pricing and Reimbursement Information) Conference on ensuring equitable access to affordable medicines took place in Vienna (Austria). Twenty-four accepted contributions were presented...
4.
Vogler S, Zimmermann N, Haasis M, Knoll V, Espin J, Mantel-Teeuwisse A, et al.
J Pharm Policy Pract
. 2024 May;
17(Suppl 1):2335492.
PMID: 38757122
Sustainable access to affordable medicines remains a public health issue globally, including for high-income countries. To foster the debate on avenues for the future, the fifth PPRI Conference held in...
5.
Arango-Luque A, Yucuma D, Castaneda C, Espin J, Becerra-Posada F
Value Health Reg Issues
. 2024 Apr;
42:100981.
PMID: 38677063
Objectives: To review and describe alternative strategies for the supply of vaccines in Latin America. Methods: We conducted a narrative review to explore and describe alternatives for equitable vaccine access...
6.
de Sequera P, Buades J, Reyes-Alcazar V, Pais B, Espin J, Tombas A, et al.
Nefrologia (Engl Ed)
. 2024 Jan;
43(6):663-667.
PMID: 38182446
No abstract available.
7.
Calleja J, Espin J, Kaushik A, Hernandez-Guerra M, Blissett R, Yehoshua A, et al.
Pharmacoecon Open
. 2023 Dec;
8(2):221-233.
PMID: 38100074
Background: In 2015, Spain launched a national eradication strategy for hepatitis C virus (HCV), resulting in the highest treatment rate in Europe and substantial reductions in HCV prevalence. However, to...
8.
Rejon-Parrilla J, Espin J, Garner S, Kniazkov S, Epstein D
Front Pharmacol
. 2023 Dec;
14:1199500.
PMID: 38089054
Advanced Therapy Medicinal Products are a type of therapies that, in some cases, hold great potential for patients without an effective current therapeutic approach but they also present multiple challenges...
9.
Garcia-Fumero R, Fernandez-Lopez C, Angel Calleja-Hernandez M, Exposito-Ruiz M, Espin J, Exposito-Hernandez J
Am J Clin Oncol
. 2023 Jul;
46(10):433-438.
PMID: 37522643
Objectives: To analyze the evolution of clinical outcomes derived from clinical trials on first-line therapies for advanced or metastatic non-small cell lung cancer (NSCLC) published between 2010 and 2020, focusing...
10.
Drummond M, Ciani O, Fornaro G, Jommi C, Dietrich E, Espin J, et al.
BMC Health Serv Res
. 2023 May;
23(1):484.
PMID: 37179322
Background: The aims of this research were to provide a better understanding of the specific evidence needs for assessment of clinical and cost-effectiveness of cell and gene therapies, and to...